Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:16273.

Propensity score matching analysis of the prognosis for the rare oxyphilic subtype of thyroid cancer (Hurthle cell carcinoma)

Yiquan Xiong, Qiuyang Zhao, Zhi Li, Shuntao Wang, Hui Guo, Zeming Liu and Tao Huang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:101362-101371. https://doi.org/10.18632/oncotarget.20732

Metrics: PDF 845 views  |   HTML 1296 views  |   ?  


Yiquan Xiong1,*, Qiuyang Zhao1,*, Zhi Li1, Shuntao Wang1, Hui Guo1, Zeming Liu1 and Tao Huang1

1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

*These authors have contributed equally to this work

Correspondence to:

Tao Huang, email: huangtaowhunion@163.com

Zeming Liu, email: 6myt@163.com

Keywords: oxyphilic thyroid carcinoma; prognosis; SEER; PSM

Received: July 18, 2017     Accepted: August 09, 2017     Published: September 08, 2017


There is controversy regarding the prognosis of patients with oxyphilic thyroid cancer (OXTC). The present study compared the prognoses of OXTC, papillary thyroid cancer (PTC), and follicular thyroid cancer (FTC), in order to provide a new perspective regarding the treatment guidelines for these diseases. We evaluated data from patients with thyroid cancer who were included in the Surveillance, Epidemiology, and End Results database between 2004 and 2013. Patient mortality was evaluated using Cox proportional hazards regression analyses and Kaplan-Meier analyses with log-rank tests. The multivariate Cox regression analysis revealed that the cancer-specific survival rate for OXTC was similar to that for PTC, but higher than that for FTC. However, after propensity score matching for relevant factors, the cancer-specific survival rate for OXTC was higher than that for PTC and FTC. This unexpected result provides new implications for the treatment of patients with OXTC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20732